In the following video, Motley Fool health care bureau chief Brenton Flynn highlights 2012 as a big year for the four biggest biotechs, but the biggest of the four, Amgen (AMGN +1.51%), tends to get lost in the mix. He shows us some of the biggest trends in the company's portfolio and pipeline that may be holding that multiple down at the moment. He also discusses information from the company's presentation at the JPMorgan conference this week about its pipeline that may be a needle-mover for the company's multiple back upwards.
